Evidence map›Paper›PMID 35272618›Full record

ArticleBMC microbiology2022

Unsupervised explainable AI for molecular evolutionary study of forty thousand SARS-CoV-2 genomes.

Yuki Iwasaki, Takashi Abe, Kennosuke Wada, Yoshiko Wada, Toshimichi Ikemura

Abstract read
In one paragraph

Article in BMC microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuki IwasakiNagahama Institute of Bio-Science and Technology, Shiga-ken, Nagahama, 526-0829, Japan.
Takashi AbeFaculty of Engineering, Niigata University, Niigata-ken, 950-2181, Japan.
Kennosuke WadaNagahama Institute of Bio-Science and Technology, Shiga-ken, Nagahama, 526-0829, Japan.
Yoshiko WadaNagahama Institute of Bio-Science and Technology, Shiga-ken, Nagahama, 526-0829, Japan.
Toshimichi IkemuraNagahama Institute of Bio-Science and Technology, Shiga-ken, Nagahama, 526-0829, Japan. t_ikemura@nagahama-i-bio.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUnsupervised AI (artificial intelligence) can obtain novel knowledge from big data without particular models or prior knowledge and is highly desirable for unveiling hidden features in big data. SARS-CoV-2 poses a serious threat to public health and one important issue in characterizing this fast-evolving virus is to elucidate various aspects of their genome sequence changes. We previously established unsupervised AI, a BLSOM (batch-learning SOM), which can analyze five million genomic sequences simultaneously. The present study applied the BLSOM to the oligonucleotide compositions of forty thousand SARS-CoV-2 genomes.

resultsWhile only the oligonucleotide composition was given, the obtained clusters of genomes corresponded primarily to known main clades and internal divisions in the main clades. Since the BLSOM is explainable AI, it reveals which features of the oligonucleotide composition are responsible for clade clustering. Additionally, BLSOM also provided information concerning the special genomic region possibly undergoing RNA modifications.

conclusionsThe BLSOM has powerful image display capabilities and enables efficient knowledge discovery about viral evolutionary processes, and it can complement phylogenetic methods based on sequence alignment.

Indexed as

COVID-19SARS-CoV-2Artificial IntelligenceEvolution, MolecularHumansPhylogenyBig dataCOVID-19OligonucleotidePCR primerTherapeutic oligonucleotideViral adaptationZoonotic virus

Identifiers

PMID35272618
PMCPMC8907386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.